CD274 and neoplasm: Building on these results, a dose expansion study (NCT04429542) of combination BCA101 and pembrolizumab in thirty-nine efficacy-evaluable patients with treatment-naïve, R/M HNSCC and with tumor PD-L1 CPS ≥ 1 reported an ORR of 54%.